{"id":110295,"date":"2017-04-18T11:01:46","date_gmt":"2017-04-18T11:01:46","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=110295"},"modified":"2017-04-18T11:01:46","modified_gmt":"2017-04-18T11:01:46","slug":"sjgrens-syndrome-pipeline-to-witness-increased-rd-investment-in-the-coming-years","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sjgrens-syndrome-pipeline-to-witness-increased-rd-investment-in-the-coming-years_110295.html","title":{"rendered":"Sjogren\u2019s Syndrome Pipeline to Witness Increased R&D Investment in the Coming Years"},"content":{"rendered":"
\"\"<\/a><\/div>\n

According to a new research report “Sjögren’s Syndrome Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments”<\/strong> published by P&S Market Research, Sjögren’s syndrome currently exhibits a pipeline of approximately 42 drug candidates.<\/p>\n

Sjögren’s syndrome pipeline analysis<\/strong><\/p>\n

The study analyzed that Sjögren’s syndrome pipeline<\/a> comprises of approximately 42 drug candidates, of which 29 drug candidates are in active stage. Among the active drug candidates, three are in Phase III stage, 10 are in Phase II stage, seven are in Phase I stage and nine are in Pre-Clinical stage. The development of 11 Sjögren’s syndrome drug candidates is found to be inactive and two drug candidates are discontinued.<\/p>\n

Browse the Report Summary at: <\/strong>https:\/\/www.psmarketresearch.com\/market-analysis\/sjogrens-syndrome-therapeutics-pipeline-analysis<\/a><\/p>\n

Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.<\/p>\n

Pipeline Insights<\/strong><\/p>\n

The pipeline of Sjögren’s syndrome has been analyzed based on the route of administration, molecule type and their phases. Among route of administration, around 24.0% pipeline active drug candidates of Sjögren’s syndrome are being developed to be administered by subcutaneous route and 21.0% are being developed to be administered by intravenous route and approximately 17% drug candidates are being developed to be administered by oral route.<\/p>\n

Many companies are involved in the development of Sjögren’s syndrome therapeutics in different phases. Some of the pharmaceutical companies involved in Sjögren’s syndrome therapeutics include Bristol-Myers Squibb Company, UCB Group, Novartis AG and GlaxoSmithKline plc. Bristol-Myers Squibb Company is developing both Phase III and Phase II drug candidates for Sjögren’s syndrome.<\/p>\n

Positive clinical results of the drug candidates for Sjögren’s syndrome<\/strong><\/p>\n

The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren’s syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05). For NS2-treated subjects, mean reductions in ichthyosis severity were greater after eight weeks of therapy than after four weeks of therapy, suggesting a disease modifying effect of NS2. NS2 was observed to be generally well tolerated and there were no significant adverse events, serious adverse events or discontinuations in the trial.<\/p>\n

Browse Report Sample at: <\/strong>https:\/\/www.psmarketresearch.com\/market-analysis\/sjogrens-syndrome-therapeutics-pipeline-analysis\/report-sample<\/a><\/p>\n

Major companies collaborate for the development of <\/strong>Sjögren’s syndrome pipeline<\/strong><\/p>\n

The research found that different companies have collaborated for the development of Sjögren’s syndrome. One of the collaborations occurred in December 2014, between Aldeyra Therapeutics, Inc. and the National Organization for Rare Disorders (NORD), a non-profit organization that helps people with rare diseases, was focused towards increasing awareness among patients suffering Sjögren-Larsson syndrome. The collaboration occurred to provide patients with opportunities to connect with each other and access information about their Sjögren-Larsson syndrome, available resources and efforts related to diagnosis and treatment.<\/p>\n

Some of the key players of Sjögren syndrome pipeline include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company, Novartis AG, Aldeyra Therapeutics, Inc., GlaxoSmithKline plc, Amgen Inc., F. Hoffmann-La Roche AG and Biogen, Inc.<\/p>\n

About P&S Market Research<\/strong><\/p>\n

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry\/business verticals.<\/p>\n

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.<\/p>\n

Web: https:\/\/www.psmarketresearch.com<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> P&S Market Research
Contact Person:<\/strong> Abhishek
Email:<\/strong> enquiry@psmarketresearch.com
Phone:<\/strong> +1-888-778-7886
Address:<\/strong>347 5th Ave. #1402- 210
City:<\/strong> New York City
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.psmarketresearch.com\/market-analysis\/sjogrens-syndrome-therapeutics-pipeline-analysis<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

According to a new research report “Sjögren’s Syndrome Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments” published by P&S Market Research, Sjögren’s syndrome currently exhibits a pipeline of approximately 42 drug candidates. Sjögren’s … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-110295","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/110295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=110295"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/110295\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=110295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=110295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=110295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}